<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962297</url>
  </required_header>
  <id_info>
    <org_study_id>VENS</org_study_id>
    <nct_id>NCT02962297</nct_id>
  </id_info>
  <brief_title>Vitamin E Versus Placebo for the Treatment of Non Diabetic Patients With Nonalcoholic Steatohepatitis</brief_title>
  <official_title>VENS is a Multicenter, Randomized, Double-masked, Placebo Parallel Controlled Trial to Evaluate the Efficacy and Safety of Treatment With Vitamin E Softgel in Non Diabetic Adults With NASH Compared to Treatment With Placebo in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>R&amp;G Pharma Studies Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Hangzhou Normal University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Medicine Co., Ltd.</source>
  <brief_summary>
    <textblock>
      VENS is a multicenter, randomized, double-masked, placebo parallel controlled trial to
      evaluate the efficacy and safety of treatment with vitamin E softgel in non diabetic adults
      with NASH compared to treatment with placebo in China.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in hepatic histology</measure>
    <time_frame>after 96 weeks of treatment</time_frame>
    <description>Improvement in hepatic histology after 96 weeks of treatment as determined by liver biopsies compared to baseline. (Independent pathological evaluation committee was charged with interpreting of the histological characteristic and that allows for assessment of changes with therapy). The definition of histologic improvement requires all three of the following criteria: ① either improvement in NAS by at least 2 points or post-treatment NAS of 3 points or less, ② at least 1 point improvement in the score for ballooning and ③ no worsening of fibrosis stages.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>NASH (Non-Alcoholic Steatohepatitis)</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin E softgel,100mg,Tid,orally, 96 weeks. All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A similar appearing placebo softgel , Vitamin E -Placebo, Tid, orally, 96 weeks, All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E softgel</intervention_name>
    <description>All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
Height and weight, waist-to-hip ratio Review of diet and exercise</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18 -75, no limitation for ethnic and gender

          2. Body Mass Index(BMI) &lt; 35 kg/m2

          3. Patients with nonalcoholic steatohepatitis (NASH) based on liver biopsy obtained
             within 6 months before randomization. The histological evidence of NASH was defined as
             Non - alcoholic fatty liver disease activity score（NAS）≥ 4 (according to Nonalcoholic
             Steatohepatitis Clinical Research Network, NASH CRN) with a minimum 1 score for
             steatosis, lobular inflammation, and hepatocyte ballooning respectively.

          4. Fibrosis stage 0-3 according to nonalcoholic steatohepatitis clinical research
             network（NASH CRN).

          5. Without history of significant alcohol consumption for a period of more than 3 months
             within 5 years (&lt;10 g/day for female and &lt; 20 g/day for male).

          6. The lab test results should meet the requirements:

             ① Alanine aminotransferase （ALT） &lt; 5 times of normal upper limit

             ② Creatinine (Cr)&lt; normal upper limit

             ③ Albumin （ALB）&gt; 3.5g/L

             ④ International normalized ratio（INR）= 0.8-1.3

             ⑤ Fasting plasma glucose(FPG) &lt; 126mg/dL（7mmol/L） and/or 2h postprandial plasma
             glucose (PPG) &lt; 200mg/dL（11.1mmol/L）and/ or HbA1C &lt; 6.5 %

          7. If a participant with hypertension, he/she was required a stable antihypertensive
             drug(s) to keep blood pressure stable.(blood pressure &lt; 140/90 mmHg) 3 months prior to
             randomization.

          8. If a participant using a statin or fibrate, he/she was required on a stable dose to
             keep lipid stable (triglyceride(TG) &lt; 1.7 mmol/L, total cholesterol (TC) &lt; 5.72
             mmol/L, LDL-c &lt; 3.64 mmol/L) 3 months prior to randomization.

          9. Women of childbearing potential: negative pregnancy test during screening or at
             randomization or willingness to use an effective form of birth control during the
             trial(at least include one barrier contraceptive method) and not breast feeding

         10. Men must agree to use an effective form of birth control during the trial(at least
             include one barrier contraceptive method)

         11. All participants are needed to sign the informed consent form.

        Exclusion Criteria:

          1. Evidence of other form of acute or chronic liver disease. (Virus hepatitis, Hereditary
             hemochromatosis, Hepatolenticular degeneration, Alcoholic liver disease, Drug-induced
             hepatopathy).

          2. History of diabetic mellitus or use of antidiabetic drugs.

          3. Known heart failure of New York Heart Association class 2, 3, or 4.

          4. Wear of cardiac pacemaker.

          5. Hypothyroidism (TSH &gt; 2 times of upper normal limit).

          6. History of disease affecting drug absorption, distribution, metabolism (inflammatory
             bowel disease, gastrointestinal surgery, chronic pancreatitis, gluten allergy,
             vagotomy).

          7. Use of anti-NASH drugs within 3 months before randomization (metformin,
             thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitor, glucagon-like
             peptide-1(GLP-1), sodium glucose contransporter2(SGLT2), S-adenosylmethionine
             -e(SAM-e), polyene phosphatidyl choline, glycyrrhizin, bicyclol, reduced glutathione,
             betaine, fish oil, silymarin,oberbic acid/ursodeoxycholic acid (OCA/UDCA),
             phosphodiesterase (PDE)-inhibitor, gemfibrozil, vitamin E, long term antibiotic (&gt;1
             week).

          8. Positivity of antibody to Human Immunodeficiency Virus.

          9. Inability to safely obtain liver biopsy.

         10. Known intolerance to vitamin E

         11. Inability to fill out diary card, to manage diet and exercise, poor compliance.

         12. Dependence or abuse of alcohol and/or drugs.

         13. Any other condition which in the opinion of investigator would impede compliance or
             hinder completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junping Shi, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Hospital of Hangzhou Normal University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shilong Xie, Bachelor</last_name>
    <phone>+86 0571-88192252</phone>
    <email>hidi9@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Ditan Hospital Capital Medical University</name>
      <address>
        <city>Beijin</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Wen Xie, bachelor</last_name>
      <phone>010-88018650</phone>
      <email>wen.xie@rg-pharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>302 Military Hospital of China</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Liu, Bachlor</last_name>
      <phone>+86 10 88018650</phone>
      <email>dan.liu@rg-pharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital Capital Medical Univercity</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Liu, Bachlor</last_name>
      <phone>+86 10 88018650</phone>
      <email>dan.liu@rg-pharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan university</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiamei Huang, Bachelor</last_name>
      <phone>+86 10 88018650</phone>
      <email>jiamei.huang@rg-pharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cai Huanzhe, bachelor</last_name>
      <phone>+86 010-88018650</phone>
      <email>charles.cai@rg-pharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial Chinese Medicine Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Wang, bachlor</last_name>
      <phone>+86 10 88018650</phone>
      <email>jing.wang@rg-pharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Wang, bachlor</last_name>
      <phone>+86 10 88018650</phone>
      <email>jing.wang@rg-pharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Hangzhou Normal University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junping Shi, Phd</last_name>
      <phone>+86 0571-88358060</phone>
      <email>13957121199@vip.126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Medical University Affiliated</name>
      <address>
        <city>Luzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiamei Huang</last_name>
      <phone>+86 10 88018650</phone>
      <email>jiamei.huang@rg-pharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijun Wang, Bachelor</last_name>
      <phone>+86 10 88018650</phone>
      <email>lijun.wang@rg-pharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junyan Li, Bachelor</last_name>
      <phone>+86 10 88018650</phone>
      <email>junyan.li@rg-pharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital of Shenyang</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The second people's Hospital of Tianjin</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiuxue Jia, Bachlor</last_name>
      <phone>+86 10 88018650</phone>
      <email>qiuxue.jia@rg-pharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Medical University</name>
      <address>
        <city>Urumqi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huan Gu, Bachelor</last_name>
      <phone>+86 10 88018650</phone>
      <email>huan.gu@rg-pharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suqin He, Bachelor</last_name>
      <phone>+86 10 88018650</phone>
      <email>suqin.he@rg-pharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital Ningxia Medical</name>
      <address>
        <city>Yinchuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haizhen Li, Bachelor</last_name>
      <phone>+86 10 88018650</phone>
      <email>haizhen.li@rg-pharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin E, Non Diabetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

